Book a Meeting

Highly Galactosylated Anti-TNFα (Ustekinumab) Antibody (CAT#: BioBet-GA-032ZP) Datasheet

Target
TNFα
Isotype
IgG1
Description
The Highly Galactosylated Anti-TNFα (Ustekinumab), a biobetter antibody contains with a high level of galactosylation.
Indication
Psoriasis
Classification
Therapeutic antibody; biobetter

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced TNFα antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
TNFA
Full Name
TNF alpha
Background
TNF is a multifunctional proinflammatory cytokine that belongs to the tumor necrosis factor (TNF) superfamily. This cytokine is mainly secreted by macrophages. TNF can bind to, and thus functions through its receptors TNFRSF1A/TNFR1 and TNFRSF1B/TNFBR. TNF is involved in the regulation of a wide spectrum of biological processes including cell proliferation, differentiation, apoptosis, lipid metabolism, and coagulation. TNF has been implicated in a variety of diseases, including autoimmune diseases, insulin resistance, and cancer. Knockout studies in mice also suggested the neuroprotective function of this cytokine.
Alternative Names
Tumor Necrosis Factor, Tumor Necrosis Factor Ligand Superfamily Member 2, Cachectin, TNF-Alpha, TNFSF2, TNF-A, TNFA, Tumor Necrosis Factor (TNF Superfamily, Member 2), Tumor Necrosis Factor Ligand 1F
Gene ID
UniProt ID
Cellular Localization
Plasma membrane, Extracellular region or secreted Cytosol
Genecards
Involvement in Disease
Its related pathways are Apoptosis Modulation and Signaling and Monoamine Transport.
Related Pathways
1.Cytokines that bind to TNFRSF1A/TNFR1 and TNFRSF1B/TNFBR. It is mainly secreted by macrophages and can cause cell death in certain tumor cell lines. It is a strong pyrogen that directly acts or stimulates the secretion of interleukin-1 to cause fever. It is related to the induction of cachexia and can stimulate cell proliferation and induce cell differentiation under certain conditions. Dephosphorylation of FOXP3 impairs the function of regulatory T cells (Treg) in rheumatoid arthritis individuals. Up-regulating the expression of protein phosphatase 1 (PP1), PP1 dephosphorylates the key Ser-418 residue of FOXP3, thereby inactivating FOXP3 and deficient in Treg cell function (PubMed:23396208). In the RT4v6 bladder cancer cell line, bcg-stimulated neutrophils combined with DIABLO/SMAC mimics are key mediators of cell death in the anticancer effect (PubMed:22517918, PubMed:16829952, PubMed:23396208). By inhibiting insulin-induced IRS1 tyrosine phosphorylation and insulin-induced glucose uptake, it induces insulin resistance in adipocytes. Induces the degradation of GKAP42 protein in adipocytes, which is partly involved in tnf-induced insulin resistance (similar). 2. The formation of TNF intracellular domain (ICD) can induce dendritic cells to produce IL12.
Function
Cancer antibody; Cell Biology and Cellular Response antibody; Immune System antibody; Metabolism antibody; Signaling Transduction antibody
Field of research
1.The soluble form derives from the membrane form by proteolytic processing. The membrane-bound form is further proteolytically processed by SPPL2A or SPPL2B through regulated intramembrane proteolysis producing TNF intracellular domains (ICD1 and ICD2) released in the cytosol and TNF C-domain 1 and C-domain 2 secreted into the extracellular space. 2.The membrane form, but not the soluble form, is phosphorylated on serine residues. Dephosphorylation of the membrane form occurs by binding to soluble TNFRSF1A/TNFR1. 3.O-glycosylated; glycans contain galactose, N-acetylgalactosamine and N-acetylneuraminic acid.
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG1
Antibody Clone
Ustekinumab
Host
Human
Species Reactivity
Human
Description
Ustekinumab, a trademark of Stellara, is a human monoclonal antibody used to treat psoriasis. It was first approved for psoriasis and active psoriatic arthritis since 2009. It is made in the Netherlands. It is an antagonist that targets subcutaneous human interleukin 12 and interleukin 23, which are natural proteins that regulate the immune system and immune-mediated inflammatory diseases.
Indication
Psoriatic arthritis aggravated
Severe Plaque psoriasis
Ulcerative Colitis, Active Moderate
Ulcerative Colitis, Active Severe
Moderate Plaque psoriasis
Moderate, active Crohn´s Disease
Severe, active Crohn´s Disease

Interleukin (IL) -12 and IL-23 are heterodimer cytokines that cause immune and inflammatory responses. Among various chronic inflammatory diseases, such as psoriasis and inflammatory bowel disease. They regulate lymphocyte function, including T helper (Th) 1 and Th17 cell subsets. Th cells can further activate downstream proinflammatory mediators and transcription factors, such as TNFα and IFNγ that drive innate and adaptive immunity. Ustekinumab's antigen-binding fragment (Fab) binds the D1 domains of the IL-12 and IL-23 p40 subunits in a 1: 1 ratio.

Psoriatic arthritis aggravated
Severe Plaque psoriasis
Ulcerative Colitis, Active Moderate
Ulcerative Colitis, Active Severe
Moderate Plaque psoriasis
Moderate, active Crohn´s Disease
Severe, active Crohn´s Disease

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK

Germany